This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): AVE-9897, CCR1 Antagonist
Description: MLN3897 (Aventis' compound code: AVE-9897) is an orally-administered small molecule designed to block CCR1. CCR1 is a chemokine receptor found on the surface of various cells in the immune system which is believed to play a role in a number of inflammatory conditions, including rheumatoid arthritis, multiple sclerosis and psoriasis.
Deal Structure: In June 2000, Millenium and Aventis (now sanofi-aventis) entered into a broad agreement in the field of inflammatory disease, which includes joint discovery, development and commercialization of small molecule drugs for the treatment of specified inflammatory diseases. MLN3897 is one of several small molecules that are part of this collaboration.
As provided in the original agreement, in North America, the two companies have agreed to share the responsibility for and cost of developing, manufacturing and marketing products arising from the alliance. Outside of North America, sanofi-aventis is responsible for and will bear the cost of developing, manufacturing and marketing products arising from the alliance. sanofi-aventis is required to pay Millenium a royalty on product sales outside of North America.
In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for...See full deal structure in Biomedtracker
Additional information available to subscribers only: